BIO Europe 2018

#BIOEurope: ‘Deal making is off the charts and the IPO window is open’

By Flora Southey contact

- Last updated on GMT

(Image: Getty/© Allard Schager)
(Image: Getty/© Allard Schager)

Related tags: Europe, Denmark, Partnership

Denmark played host to its first BIO Europe this week, welcoming 4,500 attendees from across the globe – including growing numbers from China and South Korea.

It is a good time to be in biotech, EBD Group and KNect365 Life Sciences managing director, Anna Chrisman, told delegates on Monday. “Deal making is off the charts and the IPO window is open – and that seems to be true in the US, Europe and Asia alike.

“The pace of innovation and the delivery of value to patients continues to accelerate and drug approvals are at an all-time high,” ​Chrisman added.

Biopharma-Reporter joined the biotech world in Copenhagen this week, to cover partnering trends, Chinese investment opportunities, and the ‘make or buy’ dilemma in the large molecule space.

Scroll down for live Twitter updates from the event.

Related news

Related products

show more

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Related suppliers

Follow us


View more